Clinical Trial Update: A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of Viagenpumatucel-L (HS-110) in non-small cell lung cancer was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Viagenpumatucel-L (HS-110) (Viagenpumatucel-L)

Snippet

Sponsor: Heat Biologics | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-02-05